Net sales up organically by 3.8% to € 5.3 billion EBITDA pre up organically by 16.9% to € 1.6 billion EBITDA ...
Pfizer Inc. (NYSE: PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, a...
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hyd...
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commenc...
With a renewed focus on drug prices, fast-track approvals, and ‘America First’ production, industry experts warn pharma to brace for Tr...
Financial report for the period 1 January 2024 to 30 September 2024 &nb...
Illumina, Inc. shared its financial results for the third quarter of fiscal year 2024, demonstrating resilience amidst macroeconomic challenges and...
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24%compared to the third quarter of 2023 Placed seven Growth Direct&...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported its consolidated financial results for the third quarter...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced financial r...
Innovative Trials is the second fastest-growing, woman-powered UK company in the clinical research sector and in the top 200 overall, according to ...
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 milli...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 28, ...
Roche’s latest financial report highlights its robust performance, driven by innovation in its pharmaceutical and diagnostics divisions, while navi...
© 2024 Biopharma Boardroom. All Rights Reserved.
